宫颈癌新辅助化疗的临床评价

摘要

宫颈癌新辅助化疗(NACT)在宫颈癌治疗中具有潜在的优势.近二十余年来国内外学者对宫颈癌NACT联合手术或放疗的治疗模式进行了一些探索,取得一定经验.但NACT在宫颈癌治疗中的地位仍未明确,且对其化疗方案选择目前无统一认识.现对NACT多种化疗方案应用于宫颈癌的疗效及其发展趋势进行综述,以期在分子学水平更准确地评价NACT疗效及预测化疗敏感性.%Neoadjuvant chemotherapy( NACT )has potential advantage in cervical cancer. NACT refers to systemic chemotherapy given to patients before local treatment. Scholars from both China and abroad have explored the modality therapy for NACT combined with surgery or radiotherapy on cervical cancer over the last two decades and they have learned certain experiences in this area. But the status of NACT is not clear yet and there is no consensuson how to choose its appropriate chemotherapy protocol. The latest therapeutic progress of NACT, the effect of various regimens, and their development trends now are being reviewed. In order to more accurately in molecular level,evaluate NACT treatment and predict chemotherapy sensitivity.